Meet Zongertinib (Hernexeos) – a breakthrough drug for patients with HER2‑mutant lung cancer Zongertinib (brand name: Hernexeos) is an innovative oral medication that acts as a selective HER2 receptor inhibitor…
Breakthrough Medical Vaccine for Glioblastoma (GBM): Personalized Life-Extending Immunotherapy A new international study introduces an innovative therapeutic option for glioblastoma (GBM) patients: a personalized vaccine based on the genetic analysis…
🧠 A new treatment for leptomeningeal metastases offers real hope for advanced-stage cancer patients. A groundbreaking study published in Nature Medicine and presented at ASCO 2025 shows promising clinical results…
Metastatic Triple-Negative Breast Cancer: ASCO 2025 Highlights Breakthrough Therapy Metastatic triple-negative breast cancer (TNBC) is one of the most aggressive and difficult-to-treat forms of breast cancer, with limited standard treatment…
We’re happy to share some good news – the well-known and highly respected chef Tomasz Jakubiak has returned to Poland after an extended stay at an oncology hospital in…
*💡 What's This About?* A new study published in BMC Cancer examined an innovative combination of two drugs - Pyrotinib and *Etoposide* in metronomic dosing (low continuous dosing) in patients…
What's This About? A new study published in the prestigious The Lancet Oncology examined an innovative drug called Camizestrant in women with hormone-positive (ER+) and HER2-negative metastatic breast cancer, whose…
What happens when a patient with metastatic pancreatic cancer turns to us? Metastatic pancreatic cancer is a particularly challenging disease with a complex prognosis. Standard treatments are primarily based on…
📅 Posted on September 30, 2024 💡 What's This About? A new study examined the combination of two drugs – Eribulin and Carboplatin – in patients with "triple negative" metastatic…
Posted on September 19, 2024 What's This About? 🔍 A promising new study examined the combination of two drugs, Rogaratinib Plus Atezolizumab, in patients with locally advanced or metastatic bladder cancer,…